


NG25

Chemical Properties

CAS No. :	1315355-93-1
Formula:	C ₂₉ H ₃₀ F ₃ N ₅ O ₂
Molecular Weight:	537.58
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC ₅₀ s of 149 nM and 21.7 nM, respectively.
Targets(IC ₅₀)	MAPK
In vitro	NG25 sensitizes the breast cancer cells to Dox treatment in vitro. This combination may be an effective and feasible therapeutic option maximizing Dox efficacy and meanwhile minimizing Dox side effects in treating breast cancer[1].
Cell Research	Breast cancer cells were seeded in 12-well plates at 2×10 ³ cells per well, then incubated with Dox alone or Dox with NG25 at indicated concentrations after 72h and then were cultured in fresh medium without drug. Two weeks later, cells were fixed and stained with methanol/crystal violet for 10min, and photographed. Each experiment was performed in triplicates[1].

Solubility Information

Solubility	DMSO: 16.67 mg/mL (31 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8602 mL	9.3009 mL	18.6019 mL
5 mM	0.372 mL	1.8602 mL	3.7204 mL
10 mM	0.186 mL	0.9301 mL	1.8602 mL
50 mM	0.0372 mL	0.186 mL	0.372 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Fan S, Huang X, Tong H, et al. p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression. European Journal of Pharmacology. 2022: 175277.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481